SPOTLIGHT: zolbetuximab plus chemotherapy prolongs PFS and OS in CLDN18.2+ metastatic gastric cancer | VJOncology
Zolbetuximab with mFOLFOX6 Improves Survival in Claudin 18.2-Positive Gastric Cancer
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
Astellas Pharma US on LinkedIn: Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of…
Zolbetuximab regimen extends survival in gastric, gastroesophageal junction cancer subset
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
Zolbetuximab Plus mFOLFOX6 for Gastric/GEJ Cancer
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer - Medical Conferences
Claudin-18.2 targeting by zolbetuximab: results of SPOTLIGHT in perspective - The Lancet
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
New potential standard-of-care for patients with CLDN18.2+/HER2- LA unresectable or mG/GEJ adenocarcinoma – an international perspective
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma - ScienceDirect
Zolbetuximab for CLDN18.2+ GEC - Slideset Download - ASCO GI 2023 | CCO
Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression | Evaluate
Zolbetuximab benefits subset of patients with gastric, gastroesophageal junction cancer
Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial in Treatment in Gastric Cancers - Onco'Zine
ASCO GI 2023 Phase 3 SPOTLIGHT Study Primary Results: Zolbetuximab + mFOLFOX6 as 1L Treatment for Patients With CLDN18.2+/HER2- Locally Advanced Unresectable/Metastatic Gastric or GEJ Adenocarcinoma | VuMedi
A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
Cancers | Free Full-Text | Recent Developments of Systemic Chemotherapy for Gastric Cancer
Zolbetuximab With mFOLFOX6 Meets Primary Endpoint in SPOTLIGHT Trial
Shelley Shaw on LinkedIn: Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3…
Pamela Kunz, MD on Twitter: "#GI23 📢Oral Abstract Session A starting now CLAUDIN 18.2 getting lots of air time today. 🔦SPOTLIGHT Trial: Zolbetuximab + mFOLFOX vs. PBO + mFOLFOX in pts with
